12-Week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension

European Journal of Ophthalmology

Volumn 15, Issue 5, 2005, Pages 581-590

  Goñi, Francisco J ^a,b,c  

^a HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c NONE   (Spain)

Author keywords

Brimonidine; Fixed combination; Glaucoma; Intraocular pressure; Timolol

Indexed keywords

BRIMONIDINE; EYE DROPS; TIMOLOL;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; ASTHENIA; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE BURNING; EYE PAIN; FEMALE; HEADACHE; HUMAN; HYPEREMIA; HYPERTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; VISUAL DISORDER; XEROSTOMIA;

EID: 26444614168     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210501500508     Document Type: Article

References (21)

1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40.
2. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79.
3. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-53.
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13; discussion 829-30.
5. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004; 111: 1627-35.
6. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113: 1514-7.
7. Simmons ST, Earl ML. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology 2002; 109: 307-14; discussion 314-5.
8. Zabriskie N, Netland PA. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials. Adv Ther 2003; 20: 92-100.
9. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma 2001; 10: 220-6.
10. Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003; 110: 615-24.
11. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol 1978; 96: 2045-8.
12. Cantor LB. An update on bimatoprost in glaucoma therapy. Expert Opin Pharmacother 2002; 3: 1753-62.
13. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995; 26: 233-6.
14. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health 1993; 83: 711-6.
15. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol 2000; 130: 832-3.
16. Cvenkel B, Ihan A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica 2002; 216: 175-9.
17. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18: 205-15.
18. Higginbotham EJ, Feldman R, Stiles M, Dubiner H. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002; 120: 915-22.
19. Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology 1998; 105: 1936-44.
20. Diestelhorst M, Larsson LI. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol 2004; 88: 199-203.
21. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996; 7: 80-6.